HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

Files in This Item:
J Bone Miner Metab 39 868–875.pdf3.23 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/86683

Title: Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
Authors: Shimizu, Tomohiro Browse this author →KAKEN DB
Arita, Kosuke Browse this author
Murota, Eihiro Browse this author
Hiratsuka, Shigeto Browse this author
Fujita, Ryo Browse this author
Ishizu, Hotaka Browse this author
Asano, Tsuyoshi Browse this author
Takahashi, Daisuke Browse this author
Takahata, Masahiko Browse this author →KAKEN DB
Iwasaki, Norimasa Browse this author →KAKEN DB
Keywords: Postmenopausal osteoporosis
Romosozumab
Denosumab
Bone metabolic marker
Issue Date: Sep-2021
Publisher: Springer
Journal Title: Journal of Bone and Mineral Metabolism
Volume: 39
Issue: 5
Start Page: 868
End Page: 875
Publisher DOI: 10.1007/s00774-021-01226-1
Abstract: Purpose We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy. Methods Postmenopausal osteoporosis patients with a high risk of fracture-154 in total-were recruited; their therapies were switched to ROMO or DENO from BP/naive or vitamin D (ND) (ND-ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone metabolic markers and BMD were evaluated. Results ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the ROMO groups, % changes of BMD from baseline to 12 months were associated with bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months. Conclusions ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration.
Rights: This is a post-peer-review, pre-copyedit version of an article published in Journal of Bone and Mineral Metabolism. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00774-021-01226-1
Type: article (author version)
URI: http://hdl.handle.net/2115/86683
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 清水 智弘

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University